Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Amin, Asim; Plimack, Elizabeth R.; Infante, Jeffrey R.; Ernstoff, Marc S.; Rini, Brian I.; McDermott, David F.; Knox, Jennifer J.; Pal, Sumanta K.; Voss, Martin H.; Sharma, Padmanee; Kollmannsberger, Christian; Heng, Daniel Yick Chin; Spratlin, Jennifer L.; Shen, Yun; Kurland, John F.; Gagnier, Paul; Hammers, Hans J.

doi:10.1200/jco.2014.32.15_suppl.5010

Cited by 186 publications

(142 citation statements)

References 0 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Grade 3/4 adverse events were observed in 73% of the patients, leading to discontinuation of treatment in 8 patients (24%) (Amin et al, 2014). In the pazopanib arm of the study, the ORR was 45% with a median PFS rate of 55% at 24 weeks, grade 3/4 adverse events at 60%, and a total of 4 patients (20%) discontinuing the treatment (Amin et al, 2014). Most of the grade 3/4 adverse events were related to transaminitis/hepatotoxicity, leading to discontinuation in 3 patients in the pazopanib arm.…”

Section: 332mentioning

confidence: 97%

“…In the sunitinib arm of the study, the ORR was 52%, with a median PFS rate of 78% at 24 weeks. Grade 3/4 adverse events were observed in 73% of the patients, leading to discontinuation of treatment in 8 patients (24%) (Amin et al, 2014). In the pazopanib arm of the study, the ORR was 45% with a median PFS rate of 55% at 24 weeks, grade 3/4 adverse events at 60%, and a total of 4 patients (20%) discontinuing the treatment (Amin et al, 2014).…”

Section: 332mentioning

confidence: 97%

See 1 more Smart Citation

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

Swaika

Hammond

Joseph

2015

Molecular Immunology

185

155

View full text Add to dashboard Cite

Section: 332mentioning

confidence: 97%

Section: 332mentioning

confidence: 97%

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

Swaika

Hammond

Joseph

2015

Molecular Immunology

185

155

View full text Add to dashboard Cite

“…Four dose limiting toxicities (DLTs) were observed in the pazopanib arm (elevated ALT/AST (n=3), fatigue (n=1)), while no DLTs were reported in the sunitinib arm. When nivolumab is combined with sunitinib or pazopanib [80,81], response rates are 58 and 43 %, respectively. Interestingly, grade 3-4 related toxicities were observed in 82 and 70 % in the sunitinib and pazopanib arms, respectively.…”

Section: New Therapies In Metastatic Rcc: Immunotherapy and Beyondmentioning

confidence: 99%

New advances in genitourinary cancer: evidence gathered in 2014

Suárez

Puente

Gallardo³

et al. 2015

Cancer Metastasis Rev

View full text Add to dashboard Cite

This review provides updated information published in 2014 regarding advances and major achievements in genitourinary cancer. Sections include the best in prostate cancer, renal cancer, bladder cancer, and germ cell tumors. In the field of prostate cancer, data related to treatment approach of hormone-sensitive disease, castrate-resistant prostate cancer, mechanisms of resistance, new drugs, and molecular research are presented. In relation to renal cancer, relevant aspects in the treatment of advanced renal cell carcinoma, immunotherapy, and molecular research, including angiogenesis and von Hippel-Lindau gene, molecular biology of non-clear cell histologies, and epigenetics of clear renal cell cancer are described. New strategies in the management of muscle-invasive localized bladder cancer and metastatic disease are reported as well as salient findings of biomolecular research in urothelial cancer. Some approaches intended to improve outcomes in poor prognosis patients with metastatic germ cell cancer are also reported. Results of clinical trials in these areas are discussed.

show abstract

“…For example, nivolumab has been evaluated in combination with sunitinib and pazopanib in a phase I trial (Amin et al, 2014). Nivolumab was administered at a starting dose of 2 mg/kg, which was increased at 5 mg/kg.…”

Section: Combination Strategies With Conventional Treatmentsmentioning

confidence: 99%